Pancreatic cancer

PDAC · Oncology · 4 drugs · 3 indications

Cancer of the pancreas. Mostly pancreatic ductal adenocarcinoma.

Competitive Landscape (4 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
ASP3082	ALPMY	KRAS G12D degrader	Small molecule	PO	PHASE1
Lynparza	AZN, MRK	PARP inhibitor	Small molecule	ORAL	APPROVED
Vyloy	ALPMY	CLDN18.2-targeting	Antibody	IV	APPROVED
Bizengri	GMAB	Anti-HER2/HER3 bispecific (NRG1 fusion blocker)	Bispecific antibody	IV	APPROVED

Indications (3)

CLDN18.2+ pancreatic adenocarcinoma

ASP3082 PHASE1Vyloy PHASE3

NRG1 fusion-positive pancreatic adenocarcinoma

Bizengri APPROVED

Pancreatic cancer (germline BRCA-mutated)

Lynparza APPROVED

Upcoming Catalysts

ASP3082 (Setidegrasib) - Pancreatic Cancer - Ph3 - StartCLINICAL

ALPMYBy Mar 2026

Vyloy - Global Launch TrajectoryCOMMERCIAL

ALPMY2026

ASP3082 - NSCLC - Registrational Study PreparationCLINICAL

ALPMY2026

Vyloy + Keytruda + Chemo - 1L Gastric - Ph3 - Updates (LUCERNA)CLINICAL

ALPMY2027+

Data from Supabase · Updated 2026-03-24